Abstract
Many randomized clinical trials have demonstrated that anticoagulation with dose-adjusted warfarin is safe and effective for stroke prevention in patients with atrial fibrillation (AF), and multiple guideline statements recommend anticoagulation for most patients with AF. Nonetheless, anticoagulants are substantially underused in AF patients. One reason may be the concern that the ratio of benefits to risks conferred by warfarin therapy may not be as favorable in clinical practice as in clinical trials. To address this concern, researchers examined databases from a large managed care system in …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
